�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement..

while all of the drugs work on cgrp, they don�t all work the same way. three of them target the cgrp molecule itself. aimovig goes after cgrp's receptor in the brain..

david dodick, md, neurologist, mayo clinic; chairman, american migraine foundation....